FDA TEMPO Pilot — Pre-Authorization Pathway for Generative AI Medical Devices (Updated 2026)
CONCEPTUPDATE ADDS: The FDA's TEMPO Pilot represents one approach to generative AI device regulation, but regulatory fragmentation is emerging as a critical issue. Forbes reports that there is significant disagreement between the FDA and state authorities about who should regulate AI that doctors use. The TEMPO framework emphasizes competency-based evaluation and pre-authorization clinical validation. However, individual states are simultaneously enacting their own AI healthcare regulations, creating compliance complexity for national health systems. This regulatory patchwork undermines the FDA's unified approach. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.